Get started
Author

Barbara Vogg

Observed name: B. Vogg
Institution: Hexal (Germany)
ORCID: 0009-0004-5563-8631
Observed ORCID: 0009-0004-5563-8631
OpenAlex ID: A5014886141
Efficient transgenesis in farm animals by lentiviral vectors
2003 · Andreas Hofmann, Barbara Kessler, et al. · EMBO Reports · 285
The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
2018 · Ulf Neumann, Mike Ufer, et al. · EMBO Molecular Medicine · 184
PDF
A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice
2015 · Ulf Neumann, Heinrich Rueeger, et al. · Molecular Neurodegeneration · 114
PDF
Discovery of 4-((2 S ,4 S )-4-Ethoxy-1-((5-methoxy-7-methyl-1 H -indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases
2020 · Nello Mainolfi, Takeru Ehara, et al. · Journal of Medicinal Chemistry · 71
Synthesis and NMR-studies of dinucleotides with conformationally restricted cyclic phosphotriester linkages
2001 · Anders M Sørensen, Katrine E Nielsen, et al. · Tetrahedron · 43
Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study
2024 · Sławomir Jeka, Eva Dokoupilová, et al. · Journal of Bone and Mineral Research · 23
PDF
Modeling and design of challenge tests: Inflammatory and metabolic biomarker study examples
2014 · Johan Gabrielsson, Stephan Hjorth, et al. · European Journal of Pharmaceutical Sciences · 12
The Totality of Evidence for SDZ-deno: A Biosimilar to Reference Denosumab
2024 · Barbara Vogg, Johann Poetzl, et al. · Clinical Therapeutics · 8
PDF
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males
2024 · Barbara Vogg, Johann Poetzl, et al. · Expert Opinion on Biological Therapy · 8
PDF
Plain language summary of publication to understand the ROSALIA study: a new biosimilar denosumab for bone health
2025 · Richard Eastell, Sławomir Jeka, et al. · Therapeutic Advances in Musculoskeletal Disease · 1
P1‐083: Preclinical Pharmacology of Bace Inhibitor CNP520
2016 · Ulf Neumann, Laura Helen Jacobson, et al. · Alzheimer s & Dementia · 1
P4‐363: the Bace Inhibitor Nb‐360 Has Excellent Brain Penetration and Efficacy on Amyloid‐b Load in Animal Models
2014 · Ulf Neumann, Heinrich Rueeger, et al. · Alzheimer s & Dementia · 1
PDF
Corrigendum to “The Totality of Evidence for SDZ-deno: A Biosimilar to Reference Denosumab” [Clin Ther. 2024;46:916-926]
2025 · Barbara Vogg, Johann Poetzl, et al. · Clinical Therapeutics
PDF
Pharmacokinetics and pharmacodynamics of proposed denosumab biosimilar and reference denosumab in healthy male subjects.
2023 · Barbara Vogg, Johann Poetzl, et al. · Journal of Clinical Oncology
PDF
Phase I/III study to confirm bioequivalence and safe switching of proposed biosimilar denosumab in postmenopausal osteoporosis
2020 · Jean-Jacques Body, Christie Nie, et al. · Bone Reports
PDF
Complement factor B in complex with (S)-5,7-Dimethyl-4-((2-phenylpiperidin-1-yl)methyl)-1H-indole
2019 · N. Mainolfi, T. Ehara, et al. · Worldwide Protein Data Bank
BACE inhibitor NB-360 reveals strong reduction of amyloid-β generation, robust blockade of amyloid deposition and lowering of neuroinflammation in APP transgenic mice
2015 · Ulf Neumann, Heinrich Rueeger, et al.
80 Developmental Potential of Bovine Nuclear Transfer Embryos Derived From Fetal Fibroblasts Transduced With Simian Virus 40 Large T Antigen
2004 · V. Zakhartchenko, F. Yang, et al. · Reproduction Fertility and Development
PDF
Works count: 18
Citation count: 751
H-index: 8
I10-index: 7
Year
Topic
Type